Clinical Trials Browser

NCT01384513 2026-04-15

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Classical hematologyDermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Anemia, Aplastic, Anemia, Refractory, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mastocytosis, Multiple Myeloma, Mycosis Fungoides, Myeloproliferative Disorders, Polycythemia Vera, Recurrence, Sezary Syndrome, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Leukemia, Myelomonocytic, Juvenile, Primary Myelofibrosis

Clinical Trials

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma

ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma

Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma

TAB

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

Odronextamab in Low Tumor Volume Advanced FL

MK-2140-006

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

5HTP Regulation Of Asthma In Children

NEO100 and High-Grade Meningioma

Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

SOUNDTRACK-B

SCARF-1

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

Epco, Zanu, Ritux for R/R FL or MZL

ROSEWOOD

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

AQUAx2

Mandolin

Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy

FIL_MOZART

TC011_FL_201

Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

GOLSEEK-2

A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

ZUMA-5

Epcoritamab and Rituximab for First-line Follicular Lymphoma

ZGR in TN FL

A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis

Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma

REACH 5

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies